RPRXRoyalty Pharma plc
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +14% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Lightly shorted, settled Sep 15, 2026, about a week of normal trading to cover. Down 2.1% since the previous count, up from 2.0% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RPRX is trading
Royalty Pharma plc is +59% over the past year while the S&P 500 is +18%: 41 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +14%
vs 200-day average · a clear uptrend
- RSI (14)
- 36
RSI (14) · neutral
- Below its 52-week high
- 11%
Below its 52-week high
Details›
- Last close2026-10-09
- $56.90
- 1 monthS&P 500 +2.7%
- −3.1%
- 1 yearS&P 500 +18%
- +59%
- 5 yearsS&P 500 +88%
- +61%
- vs 50-day average$59.13
- −3.8%
- 52-week high
- $63.98
- 52-week low
- $34.37
- Annualised volatility
- 24%
| Year | Return |
|---|---|
| 2026 (year to date) | +49% |
| 2025 | +55% |
| 2024 | −6.4% |
| 2023 | −27% |
| 2022 | +0.99% |
| 2021 | −19% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 4 of 6 | +4.4% |
| Feb | 6 | 3 of 6 | +2.7% |
| Mar | 6 | 3 of 6 | −1.7% |
| Apr | 6 | 4 of 6 | +1.5% |
| May | 6 | 2 of 6 | −0.88% |
| Jun | 6 | 3 of 6 | +0.35% |
| Jul | 7 | 5 of 7 | +0.86% |
| Aug | 7 | 3 of 7 | −0.78% |
| Sep | 7 | 1 of 7 | −3.8% |
| Oct | 7 | 3 of 7 | +0.04% |
| Nov | 6 | 5 of 6 | +5.0% |
| Dec | 6 | 3 of 6 | +0.60% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.